Archive
FTSE 100 makes good ground despite Brexit talk
Footsie was buoyed by a good start to the week;s trading on Wall Street
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 50 of 55
FTSE100 posts solid gains as Brexit talks slays sterling
FTSE 100 climbed 76 points to 6,026 despite a tough day for the pound
FTSE 100 in ton-up mode
Miners lead the march of the blue-chips while among the small caps it is more a case of the salsa
AstraZeneca gets US boost for bladder cancer drug
Drug group gets "breakthrough therapy" designation for durvalumab in the US
Investments and investor services
London shares take cue from strong Wall Street performance
The FTSE 100 Index rose in early trading after the Dow Jones Industrial Average closed 223 points ahead
Trending - Today's unfounded big pharma merger rumor is ...
A whisper to a scream ... rumors of another big pharma merger are gaining volume
Archive
FTSE 100 lifted by resource stocks
Resource stocks were back in favour big-time today, helped by a softer US sollar
Market bounces amid oil supply cut talk
The FTSE 100 Index was 56.86 points up at 5894 at lunchtime
Investments and investor services
Footsie climbs back above 5,900 as oil prices rebound
The FTSE 100 Index gained 64.07 points to 5901 in early trading
Risers & Fallers: First Quantum, Galasys, IPSA, Motive Television, Plethora Solutions, Tribal Group
AstraZeneca is on a downer after it warns revenue and profits will be lower this year than last but Shell keeps going well
AstraZeneca's earnings rise in 2015 but sees fall this year
Drug group forecast total 2016 revenue and core EPS to decline in low to mid-single digit percentage terms
Thurday's agenda - Shell latest big oiler to open up results can
After BP's results on Tuesday, which took the market by surprise, traders will undoubtedly be anxious about Shell's figures on Thursday at a time when the oil market is in turmoil.
Week Ahead: Big oil and big pharma to the fore
Big oil and big pharma will wrestle for the limelight. On the economic front, the big events are the Bank of England's interest rate decision and US non-farm payrolls.
Archive
BAE downgraded as Credit Suisse doubts Saudi orders
BAE Systems, Burberry, Next, Smith & Nephew, AstraZeneca and Britvic are all in the broker spotlight on Tuesday.
Shire finally ties up US$32bn Baxalta deal
Two drug groups to merge to create a rare disease specialist
e-Therapeutics hires life sciences veteran as chairman
Professor Malcolm Young is stepping down as chairman but will remain in his role as chief executive.
Archive
Barclays pharma experts bullish on Shire and Glaxo
Shares in drug giants Glaxo and Shire should stay in fine heath this year, Barclays says
Archive
FTSE 100 rises 60 points despite resources millstone
While it is unlikely the Footsie will finish the year in credit, three more days of 60 points gains will see it go close
House builders wanted as north of England surveys flood damage
Flood damage in the north of England could see a lot of work coming the way of Britain's house builders
The drugs are working for the Footsie
The strength of pharma stocks more than outweighed the softness of commodities plays early doors